Patient Characteristics
Patient no. | Age (y) | iPSA (ng/mL) | Prostate volume (mL) | Days from mpMRI to surgery | Days from PSMA PET/CT to surgery | Histopathology TNM staging | Gleason-score/WHO group | Tumor volume (percentage of the whole prostate) | PCa SUVmax (1 h after injection) | PCa SUVmax (3 h after injection) | Normal tissue SUVmax |
1 | 77 | 40.0 | 50 | 54 | 21 | pT3b, pN1(4/14), L1, V0, Pn1, R1 | 4 + 5 = 9/5 | 30% | 54.9 | 76.2 | 2.8 |
2 | 55 | 14.0 | 66 | 97 | 38 | pT3b, pN1(5/40), L1, V0, Pn1, R1 | 4 + 5 = 9/5 | 45% | 10.9 | 14.8 | NA |
3 | 65 | 13.9 | 52 | 193 | 56 | pT3b, pN1(1/41), L0, V0, Pn1, RX | 4 + 5 = 9/5 | 10% | 24.3 | 30.2 | 2.7 |
4 | 64 | 10.0 | 40 | 116 | 1 | pT3b, pN1(3/48), L1, V0, Pn1, R1 | 4 + 5 = 9/5 | 35% | 18.9 | 27.5 | 2.9 |
5 | 64 | 12.2 | 23 | 66 | 19 | pT3a, pN1(3/57), L1, V1, Pn1, R1 | 4 + 3 = 7b/3 | 10% | 13.0 | 22.6 | 2.9 |
6 | 62 | 8.5 | 26 | 73 | 3 | pT3a, pN0(0/21), L0, V0, Pn1, R1 | 3 + 4 = 7a/2 | 15% | 15.5 | 27.5 | 3.6 |
7 | 69 | 5.8 | 50 | 147 | 26 | pT3a, pN0(0/32), L0, V0, Pn0, R0 | 4 + 5 = 9/5 | 15% | 36.7 | 58.6 | 3.0 |
8 | 73 | 31.0 | 47 | ——– | 6 | pT3a, pN0(0/27), L0, V0, Pn1, R1 | 3 + 4 = 7a/2 | 30% | 16.3 | 19.6 | 3.5 |
9 | 76 | 16.8 | 100 | 105 | 21 | pT2c, pN1(3/40), L1, V0, Pn1, R0 | 4 + 5 = 9/5 | 20% | 10.6 | ——– | 2.5 |
10 | 72 | 11.2 | 49 | 61 | 26 | pT3b, pN1(5/61), L1, V0, Pn1, R1 | 4 + 5 = 9/5 | 70% | 15.5 | 20.3 | NA |
iPSA = initial PSA; WHO = World Health Organization; NA = not applicable.